Sinopharm and China Kexing have submitted data on two new coronal vaccines developed by Sinopharm and China Kexing to the WHO for evaluation of the WHO emergency use list, experts from the World Health Organization said Tuesday, Xinhua reported.
It is expected to be announced as soon as March
Katherine O’Brien, who director of immunization, vaccines and biological products, said at the press conference that at present, two kinds of Chinese vaccine products are being evaluated by who’s emergency use list, namely, the Xinguan inactivated vaccine from Sinopharm group and China Kexing company.
O’Brien said the who also expects China’s new vaccine data to pass the organization’s policy assessment.
Unlike the emergency use list assessment from WHO vaccine regulatory authorities, the policy assessment is conducted separately by the WHO Strategic Advisory Panel on immunization, which will make recommendations on how to use the relevant vaccines. Previously, the expert group has carried out policy evaluation on Pfizer’s and Modena’s vaccines and given suggestions on their use.
According to the latest WHO documents, Sinopharm vaccine is in the process of who emergency use list evaluation. Kexing company has submitted vaccine evaluation data in mid January, and more documents are expected to be submitted by the end of this month. The final evaluation results of the two vaccines are expected to be released as early as March.